To investigate to what extent asymptomatic vs symptomatic prenatal Zika virus infections contribute to birth defects, we identified 3 prospective and 8 retrospective studies. The ratio varied greatly in the retrospective studies, most likely due to recruitment and recall bias. The prospective studies revealed a ratio of 1:1 for asymptomatic vs symptomatic maternal Zika infections resulting in adverse fetal outcomes.
Ever since the causal relationship between prenatal Zika virus (ZIKV) infection and microcephaly (and other serious brain anomalies) was established, the research focus has been on defining the full spectrum of defects caused by prenatal Zika virus infection, determining the relative and absolute risks of adverse outcomes among fetuses whose mothers were infected at different times during pregnancy and factors associated with adverse fetal outcomes [1] . An additional important research question is whether asymptomatic infections during pregnancy can also lead to congenital Zika syndrome (CZS), and the extent of this risk in comparison with symptomatic prenatal ZIKV infections. Based on a seroprevalence study in Yap Island, an asymptomatic-to-symptomatic ratio of 4:1 has been postulated in the general population [2] . However, this ratio was derived from nonspecific serological assays. Furthermore, such ratios may vary in different settings. For example, for dengue virus infections, another flavivirus transmitted by the same vector, asymptomatic-to-symptomatic ratios depend on age and viral virulence [3] . Pregnancy may also be associated with more clinical manifestations than reported in the general population. Knowing the proportion of asymptomatic ZIKV infection in pregnant women, and the extent to which asymptomatic ZIKV infections lead to birth defects, is critical to understanding the evolving epidemiology, selecting the best diagnostic approach in pregnant women, and informing vaccine development. Setting up sufficiently large prospective cohort studies of pregnant women living or visiting countries during a Zika epidemic will be the best study design to accurately determine these proportions. Indeed, such studies are being funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (https://www.nichd.nih.gov/news/releases/ Pages/zika_zip_06202016.aspx) and the European Commission [4] , but definitive answers will not be able for another couple of years. In the absence of such results, we did a literature review to assess whether asymptomatic ZIKV infection during pregnancy is associated with CZS/microcephaly and to estimate the risk.
THE STUDY
Using the search terms "Zika" AND/OR "pregnancy" AND/ OR "microcephaly, " we identified 898 papers between 1947 and September 2017. We reviewed all titles and abstracts of publications and selected those articles that fulfilled the following eligibility criteria: original articles, birth outcomes from pregnant women with prenatal laboratory-confirmed ZIKV infection where clinical symptoms and the absence of clinical symptoms were reported. Eligible study designs were case series, case-control studies (in which the case was congenital Zika syndrome or microcephaly and presence or absence of symptoms during pregnancy was described), prospective studies following up returning travelers, and cohort studies. We excluded all studies where women were recruited only because of rash or other symptoms. We identified 11 articles published from 2016 to 2017 conducted in 3 countries (Brazil, Colombia, and the United States) that fulfilled our inclusion criteria. Using a standardized tool, we extracted the following information: study design, year of publication, study location, period of study, study population, clinical symptoms in mothers, laboratory confirmation of ZIKV infection in mothers, adverse fetal outcome, and frequency of such outcomes in neonates. Table 1 shows that the studies can be classified into those that recruit pregnant women and prospectively ascertain fetal outcomes [5] [6] [7] and those studies that recruit neonates with CZS or microcephaly and establish retrospectively whether the mother had symptoms compatible with a ZIKV infection [8] [9] [10] [11] [12] [13] [14] [15] . The US cohort of pregnant women with laboratory-confirmed ZIKV infections offered the highest quality of evidence as the study was prospective in nature; women were enrolled 11/141 (7.8%) symptomatic pregnancies had birth defects compared with 12/102 (11.8%) asymptomatic pregnancies.
Out of 972 completed pregnancies, 51 (5%) reported ZIKV-associated birth defects. The proportion was higher among laboratory-confirmed cases, 10% (24/250). Birth defects were reported in a higher proportion of fetuses or infants whose mothers were infected during the first trimester (15% Case series 13 infants with lab confirmation and normal head size 6/13 of the mothers reported rash between the second and fifth months of pregnancy.
6 infants had craniofacial disproportion (3 had redundant skin on the scalp at birth, and 3 infants had hip dysplasia). 11/13 infants had postnatal microcephaly, and all neuroimaging showed evidence of decreased brain volume. during pregnancy without prior knowledge about birth outcome, which minimizes recall bias for "Zika-like symptoms" compared with retrospective case-control studies and case series [5] [6] [7] . In the 3 prospective studies reporting on 442 [5] to 2549 [7] completed pregnancies, the proportion of symptomatic maternal ZIKV infections ranged from 38% to 61%. In the first report, 6% of asymptomatic and equally 6% of symptomatic maternal ZIKV infections resulted in CZS [5] ; in the second report, 5% of women were symptomatic and 4% were asymptomatic [6] ; and in the most recent report, 5% of women were symptomatic and 7% were asymptomatic [7] . In other words, the ratio of asymptomatic to symptomatic ZIKV infections resulting in adverse fetal outcomes is about 1:1. Among the completed 2549 pregnancies, there was no difference in the percentage of birth defects (between symptomatic and asymptomatic women) in the subgroup of laboratory-confirmed Zika infection [7] . The retrospective studies also consistently found that a substantial proportion of mothers of neonates with CZS reported no symptoms and so presumably had an asymptomatic prenatal ZIKV infection; however, the proportion of symptomatic vs asymptomatic women varied greatly between studies. This variation can partially be explained by the case definition: Some studies considered fever and at least 1 additional sign or symptom; in other studies, the case definition included only 1 symptom (usually rash). Another variation presented was the definition of the outcome. In some case series, all the mothers had laboratory-confirmed Zika infection during their pregnancy [9] ; in other studies, the case definition was based on brain imaging consistent with ZIKV infection [11] . An additional explanation is recall bias and recruitment bias that would favor a history of rash or other symptoms compatible with ZIKV disease. In the retrospective studies, the proportion of CZS as a result of symptomatic maternal ZIKV infection ranged from 88.9% [10] to 34%, translating into a ratio of symptomatic-to-asymptomatic maternal infections between 5:1 and 1:2.
CONCLUSIONS
This review documents that asymptomatic prenatal ZIKV infection can result in CZS. The retrospective studies (case-control and case series) showed a variable risk, and this variation reflects a combination of recruitment bias, recall bias, and varying case definitions. Prospective cohort studies are less affected by such bias, and the only published cohort studies to date are based on the US Zika Pregnancy and Infant Registry, which reported roughly similar numbers of CZS in neonates born to women with symptomatic and asymptomatic ZIKV infection.
Our findings have several implications. First, the ratio of asymptomatic-to-symptomatic infections in pregnancy appears to be lower in pregnant travelers returning to the United States compared with the population-based seroprevalence study on Yap Island, although recruitment bias toward symptomatic women may have played a role in the higher proportion of symptomatic infections seen in the US study. Second, it highlights that surveillance of women based on rash or other symptoms is not sufficient, and screening all pregnant women for ZIKV exposure is necessary in areas or countries where ZIKV is circulating. Taking into account that currently available diagnostics for ZIKV are suboptimal and hence may miss maternal ZIKV infections, birth defect surveillance for CZS needs to be strengthened. Third, given the low viremia levels, more sensitive diagnostic tools are urgently needed to improve maternal sceening. Fourth, as asymptomatic infections are likely associated with lower viremia, our findings suggest that even low levels of viremia could lead to CZS. A high bar is hence required for Zika vaccine development, possibly necessitating a vaccine that achieves complete reduction or prevention of viremia, for example, sterilizing immunity. The demonstration of a clinical benefit of a vaccine is usually based on a clinical end point. Our findings would justify selecting ZIKV infection rather than ZIKV disease as a clinical end point. However, the disadvantage of such an end point is the need for frequent sampling to detect asymptomatic infections, confounded by the limitations of current diagnostic assays. Perhaps protection against infection could be studied in at least a subset of an efficacy trial where the primary end point would be clinical ZIKV disease. Lastly, the ratio of asymptomatic-to-symptomatic infections was best described in the US cohort but needs to be confirmed by larger prospective cohort studies in endemic countries.
